Investors.aileronrx.com

Aileron Therapeutics Announces Positive Data from Cohort 1 of …

WEBLow-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and …

Actived: 9 days ago

URL: https://investors.aileronrx.com/news-releases/news-release-details/aileron-therapeutics-announces-positive-data-cohort-1-phase-1b

Aileron Therapeutics Announces Initiation of Randomized, Double …

WEBInvestor Contacts: Media Contact: Richard Wanstall, SVP Chief Financial Officer Liz Melone: Aileron Therapeutics 617-256-6622: 617-995-0900: [email protected]

Category: Health Go Health

Aileron Therapeutics to Present New Clinical Data at ESMO Virtual

WEBPreliminary findings from ongoing Phase 1 healthy volunteer study will include data relating to mechanism of action; optimal dose; and time to onset, duration …

Category: Health Go Health

Revolutionizing Supportive Care: The Promise of Precision

WEBSpeakers: Manuel Aivado, M.D., Ph.D. President and Chief Executive Officer, Aileron Therapeutics Ralf Paus, MD, FRSB Professor of Dermatology Dr. Phillip Frost …

Category: Health Go Health

Aileron Therapeutics Announces Expansion of Scientific Advisory …

WEBCAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for …

Category: Health Go Health

Aileron Therapeutics Strengthens Board of Directors with …

WEBWATERTOWN, Mass., June 24, 2019 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ: ALRN), the clinical-stage leader in the field of stabilized cell-permeating …

Category: Health Go Health

investors.aileronrx.com

WEBSecurities and Exchange Commission. Washington, D.C.20549. Schedule 13G. Under the Securities Exchange Act of 1934 (Amendment No. 0)* March 31, 2019 (Date of event …

Category: Health Go Health

Aileron Therapeutics Appoints Donald Dougherty as Senior Vice …

WEBCAMBRIDGE, MA—June 15, 2017—Aileron Therapeutics, a clinical-stage biopharmaceutical company developing a novel class of therapeutics called stapled …

Category: Health Go Health

Aileron Therapeutics Announces Positive Data from Cohort 1 …

WEBlatter of which are believed to be causative in onset and aggravation of the disease. These findings underscore the promise of LTI-03 to combat the

Category: Health Go Health

Aileron Therapeutics Reports Second Quarter 2019 Financial Results

WEBEnrollment in Phase 2a expansion cohort testing ALRN-6924 in combination with Pfizer’s IBRANCE® (palbociclib) in MDM2-amplified cancers ongoing and ahead of …

Category: Cancer Go Health

Bank of America Merrill Lynch 2018 Health Care Conference …

WEBAileron - Corporate Highlights 3 Confidential • Clinical-stage leader in stapled peptide therapeutics for cancer and other diseases • Clinical proof-of-concept with multiple …

Category: Cancer Go Health

Aileron Therapeutics to Host Virtual KOL Investor Event on May …

WEBBOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and …

Category: Health Go Health

Aileron Therapeutics Reports First Quarter 2018 Financial Results

WEBCAMBRIDGE, Mass., May 09, 2018 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq:ALRN), the clinical-stage leader in the field of stapled peptide therapeutics for …

Category: Health Go Health

LTI-03 Data Call

WEBPhase 1b Clinical Trial Design (Status: In Process) Screening LTI-03 Dry Powder Inhalation Up to 21 Days 14 Days 7 Days Follow-Up In Clinic Visits -D21 D7 …

Category: Health Go Health